NEW YORK (GenomeWeb News) — Affymetrix earlier this month disclosed that it had hired Kevin King as president of its life science business, and as executive vice president
 
King, 50 years old, previously worked at Thomson Corporation where he served as president and CEO of Thomson Healthcare from February 2005 to June 2006. 
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.